American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

XTL BIOPHARMACEUTICALS LTD

NEW YORK, New York
Public · NASDAQ: XTLB
2 employees

Visit website Follow

$4.9MMarket cap

2Employees

XTLBNASDAQ

2005IPO

About XTL BIOPHARMACEUTICALS LTD

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.